RNA-Based Vaccines in Cancer Immunotherapy

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  McNamara, Megan A ^a   Nair, Smita K ^a   Holl, Eda K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; DNA VACCINE; MESSENGER RNA; PROTAMINE; RNA VACCINE; TUMOR ANTIGEN; CANCER VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; GENE GUN; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA STRUCTURE; ANIMAL; ANTIGEN PRESENTATION; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DENDRITIC CELL; DISEASE MODEL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; RNA, MESSENGER;

EID: 84948807547     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/794528     Document Type: Review

References (110)

1. I. Mellman, G. Coukos, and G. Dranoff, "Cancer immunotherapy comes of age," Nature, vol. 480, no. 7378, pp. 480-489, 2011.
2. D.M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy," Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
3. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, "Adoptive cell transfer: a clinical path to effective cancer immunotherapy," Nature Reviews Cancer, vol. 8, no. 4, pp. 299-308, 2008.
4. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma," The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
5. J. Brahmer, K. L. Reckamp, P. Baas et al., "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer," The New England Journal of Medicine, vol. 373, no. 2, pp. 123-135, 2015.
6. P. W. Kantoff, C. S. Higano, N. D. Shore et al., "Sipuleucel-T immunotherapy for castration-resistant prostate cancer," The New England Journal of Medicine, vol. 363, no. 5, pp. 411-422, 2010.
7. G. Middleton, P. Silcocks, T. Cox et al., "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial," The Lancet Oncology, vol. 15, no. 8, pp. 829-840, 2014.
8. C. Butts, M. A. Socinski, P. L. Mitchell et al., "Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, doubleblind, phase 3 trial," The Lancet Oncology, vol. 15, no. 1, pp. 59-68, 2014.
9. D. J. Schwartzentruber, D. H. Lawson, J. M. Richards et al., "gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma," The New England Journal of Medicine, vol. 364, no. 22, pp. 2119-2127, 2011.
10. L. H. Butterfield, "Cancer vaccines," The BMJ, vol. 350, article h988, 2015.
11. C. Guo, M. H. Manjili, J.R. Subjeck, D. Sarkar, P. B. Fisher, and X. Wang, "Therapeutic cancer vaccines: past, present, and future," Advances in Cancer Research, vol. 119, pp. 421-475, 2013.
12. I. Melero, G. Gaudernack, W. Gerritsen et al., "Therapeutic vaccines for cancer: an overview of clinical trials," Nature Reviews Clinical Oncology, vol. 11, no. 9, pp. 509-524, 2014.
13. J. Rice, C. H. Ottensmeier, and F. K. Stevenson, "DNA vaccines: precision tools for activating effective immunity against cancer," Nature Reviews Cancer, vol. 8, no. 2, pp. 108-120, 2008.
14. J. B. Ulmer, P. W. Mason, A. Geall, and C. W. Mandl, "RNAbased vaccines," Vaccine, vol. 30, no. 30, pp. 4414-4418, 2012.
15. + T cells by dendritic cells transfected with mRNA encoding cytoplasm-or lysosometargeted Nef," Blood, vol. 107, no. 5, pp. 1963-1969, 2006.
16. + T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag," European Journal of Immunology, vol. 37, no. 8, pp. 2164-2173, 2007.
17. + T cells in melanoma patients," Molecular Therapy, vol. 20, no. 5, pp. 1063-1074, 2012.
18. S. Gurunathan, D.M. Klinman, and R. A. Seder, "DNAvaccines: immunology, application, and optimization," Annual Review of Immunology, vol. 18, pp. 927-974, 2000.
19. H. L. Robinson, "DNA vaccines: basic mechanism and immune responses (Review)," International Journal of Molecular Medicine, vol. 4, no. 5, pp. 549-555, 1999.
20. M. A. Kutzler and D. B. Weiner, "DNAvaccines: ready for prime time?" Nature Reviews Genetics, vol. 9, no. 10, pp. 776-788, 2008.
21. C. Coban, K. Kobiyama, T. Aoshi et al., "Novel strategies to improveDNA vaccine immunogenicity," Current Gene Therapy, vol. 11, no. 6, pp. 479-484, 2011.
22. K. Eisenächer, C. Steinberg, W. Reindl, and A. Krug, "The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity," Immunobiology, vol. 212, no. 9-10, pp. 701-714, 2008.
23. A. J. Shatkin, "Capping of eucaryotic mRNAs," Cell, vol. 9, no. 4, part 2, pp. 645-653, 1976.
24. F. Mignone, C. Gissi, S. Liuni, and G. Pesole, "Untranslated regions of mRNAs," Genome Biology, vol. 3, no. 3, Article ID REVIEWS0004, 2002.
25. R. C. Deo, J. B. Bonanno, N. Sonenberg, and S. K. Burley, "Recognition of polyadenylate RNA by the poly(A)-binding protein," Cell, vol. 98, no. 6, pp. 835-845, 1999.
26. Y. Furuichi, A. LaFiandra, and A. J. Shatkin, "5′-Terminal structure and mRNA stability," Nature, vol. 266, no. 5599, pp. 235-239, 1977.
27. N. Sonenberg, M. A. Morgan, W. C. Merrick, and A. J. Shatkin, "A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5′-terminal cap in mRNA," Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 10, pp. 4843-4847, 1978.
28. A. E. Pasquinelli, J. E. Dahlberg, and E. Lund, "Reverse 5′ caps in RNAs made in vitro by phage RNA polymerases," RNA, vol. 1, no. 9, pp. 957-967, 1995.
29. J. Stepinski, C. Waddell, R. Stolarski, E. Darzynkiewicz, and R. E. Rhoads, "Synthesis and properties of mRNAs containing the novel 'anti-reverse' cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl(33′-deoxy)GpppG," RNA, vol. 7, no. 10, pp. 1486-1495, 2001.
30. F. T. Zohra, E. H. Chowdhury, S. Tada, T. Hoshiba, and T. Akaike, "Effective delivery with enhanced translational activity synergistically acceleratesmRNA-based transfection," Biochemical and Biophysical Research Communications, vol. 358, no. 1, pp. 373-378, 2007.
31. P. Bernstein, S. W. Peltz, and J. Ross, "The poly(A)-poly(A)- binding protein complex is a major determinant of mRNA stability in vitro," Molecular and Cellular Biology, vol. 9, no. 2, pp. 659-670, 1989.
32. A.-C. Gingras, B. Raught, and N. Sonenberg, "eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation," Annual Review of Biochemistry, vol. 68, pp. 913-963, 1999.
33. S. Holtkamp, S. Kreiter, A. Selmi et al., "Modification of antigenencoding RNA increases stability, translational efficacy, and Tcell stimulatory capacity of dendritic cells," Blood, vol. 108, no. 13, pp. 4009-4017, 2006.
34. D. Munroe and A. Jacobson, "mRNA Poly(A) tail, a 3′ enhancer of translational initiation," Molecular and Cellular Biology, vol. 10, no. 7, pp. 3441-3455, 1990.
35. M. Mockey, C. Gonçalves, F. P. Dupuy, F. M. Lemoine, C. Pichon, and P. Midoux, "mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level," Biochemical and Biophysical Research Communications, vol. 340, no. 4, pp. 1062-1068, 2006.
36. I. Y. Tcherepanova, M. D. Adams, X. Feng et al., "Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion," BMC Molecular Biology, vol. 9, article 90, 2008.
37. P. A. Krieg and D. A. Melton, "Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs," Nucleic Acids Research, vol. 12, no. 18, pp. 7057-7070, 1984.
38. R. W. Malone, P. L. Felgner, and I. M. Verma, "Cationic liposome-mediated RNA transfection," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 16, pp. 6077-6081, 1989.
39. Z. Wang, N. Day, P. Trifillis, and M. Kiledjian, "An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro," Molecular and Cellular Biology, vol. 19, no. 7, pp. 4552-4560, 1999.
40. Y. Zhao, E. Moon, C. Carpenito et al., "Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor," Cancer Research, vol. 70, no. 22, pp. 9053-9061, 2010.
41. S. Kreiter, A. Selmi, M. Diken et al., "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity," Cancer Research, vol. 70, no. 22, pp. 9031-9040, 2010.
42. S. Kreiter, A. Selmi, M. Diken et al., "Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals," The Journal of Immunology, vol. 180, no. 1, pp. 309-318, 2008.
43. V. Hornung, J. Ellegast, S. Kim et al., "5′-Triphosphate RNA is the ligand for RIG-I," Science, vol. 314, no. 5801, pp. 994-997, 2006.
44. K. Karikó, M. Buckstein, H. Ni, and D. Weissman, "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA," Immunity, vol. 23, no. 2, pp. 165-175, 2005.
45. K. Karikó, H. Muramatsu, F. A. Welsh et al., "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability," Molecular Therapy, vol. 16, no. 11, pp. 1833-1840, 2008.
46. B. R. Anderson, H. Muramatsu, S. R. Nallagatla et al., "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation," Nucleic Acids Research, vol. 38, no. 17, pp. 5884-5892, 2010.
47. K. Karikó, H. Muramatsu, J. Ludwig, and D. Weissman, "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA," Nucleic Acids Research, vol. 39, no. 21, article e142, 2011.
48. D. W. Pack, A. S. Hoffman, S. Pun, and P. S. Stayton, "Design and development of polymers for gene delivery," Nature Reviews Drug Discovery, vol. 4, no. 7, pp. 581-593, 2005.
49. R. Juliano, M. R. Alam, V. Dixit, and H. Kang, "Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides," Nucleic Acids Research, vol. 36, no. 12, pp. 4158-4171, 2008.
50. J.A. Wolff, R.W. Malone, P. Williams et al., "Direct gene transfer into mousemuscle in vivo," Science, vol. 247, no. 4949, part 1, pp. 1465-1468, 1990.
51. R. M. Conry, A. F. LoBuglio, M. Wright et al., "Characterization of a messenger RNA polynucleotide vaccine vector," Cancer Research, vol. 55, no. 7, pp. 1397-1400, 1995.
52. J.-P. Carralot, J. Probst, I. Hoerr et al., "Polarization of immunity induced by direct injection of naked sequence-stabilizedmRNA vaccines," Cellular and Molecular Life Sciences, vol. 61, no. 18, pp. 2418-2424, 2004.
53. J. Steitz, C. M. Britten, T. Wölfel, and T. Tüting, "Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2," Cancer Immunology, Immunotherapy, vol. 55, no. 3, pp. 246-253, 2006.
54. S. Kreiter, M. Diken, A. Selmi et al., "FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines," Cancer Research, vol. 71, no. 19, pp. 6132-6142, 2011.
55. M. Fotin-Mleczek, K. M. Duchardt, C. Lorenz et al., "Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity," The Journal of Immunotherapy, vol. 34, no. 1, pp. 1-15, 2011.
56. I. Hoerr, R. Obst, H.-G. Rammensee, and G. Jung, "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies," European Journal of Immunology, vol. 30, no. 1, pp. 1-7, 2000.
57. J. Houseley and D. Tollervey, "The many pathways of RNA degradation," Cell, vol. 136, no. 4, pp. 763-776, 2009.
58. J. Probst, S. Brechtel, B. Scheel et al., "Characterization of the ribonuclease activity on the skin surface," Genetic Vaccines and Therapy, vol. 4, article 4, 2006.
59. P. Qiu, P. Ziegelhoffer, J. Sun, and N. S. Yang, "Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization," Gene Therapy, vol. 3, no. 3, pp. 262-268, 1996.
60. J. Dileo, T. E. Miller Jr., S. Chesnoy, and L. Huang, "Gene transfer to subdermal tissues via a new gene gun design," Human Gene Therapy, vol. 14, no. 1, pp. 79-87, 2003.
61. B. Scheel, S. Aulwurm, J. Probst et al., "Therapeutic anti-tumor immunity triggered by injections of immunostimulating singlestrandedRNA," European Journal of Immunology, vol. 36, no. 10, pp. 2807-2816, 2006.
62. B. Scheel, R. Teufel, J. Probst et al., "Toll-like receptor-dependent activation of several human blood cell types by protaminecondensed mRNA," European Journal of Immunology, vol. 35, no. 5, pp. 1557-1566, 2005.
63. A. E. Sköld, J. J. van Beek, S. P. Sittig et al., "Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets," Cancer Immunology, Immunotherapy, vol. 64, no. 11, pp. 1461-1473, 2015.
64. B. Weide, S. Pascolo, B. Scheel et al., "Direct injection of protamine-protectedmRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients," Journal of Immunotherapy, vol. 32, no. 5, pp. 498-507, 2009.
65. S. Kreiter, M. Diken, A. Selmi, Ö. Türeci, and U. Sahin, "Tumor vaccination using messenger RNA: prospects of a future therapy," Current Opinion in Immunology, vol. 23, no. 3, pp. 399-406, 2011.
66. U. Sahin, K. Karikó, and Ö. Türeci, "mRNA-based therapeutics-developing a new class of drugs," Nature Reviews Drug Discovery, vol. 13, no. 10, pp. 759-780, 2014.
67. T. Schlake, A. Thess, M. Fotin-Mleczek, and K.-J. Kallen, "Developing mRNA-vaccine technologies," RNA Biology, vol. 9, no. 11, pp. 1319-1330, 2012.
68. E. J. Sayour, L. Sanchez-Perez, C. Flores, and D. A. Mitchell, "Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics," Journal for Immunotherapy of Cancer, vol. 3, article 13, 2015.
69. T. Bettinger and M. L. Read, "Recent developments in RNAbased strategies for cancer gene therapy," Current Opinion in Molecular Therapeutics, vol. 3, no. 2, pp. 116-124, 2001.
70. D. Lu, R. Benjamin, M. Kim, R. M. Conry, and D. T. Curiel, "Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors," Cancer Gene Therapy, vol. 1, no. 4, pp. 245-252, 1994.
71. L. Wasungu and D. Hoekstra, "Cationic lipids, lipoplexes and intracellular delivery of genes," Journal of Controlled Release, vol. 116, no. 2, pp. 255-264, 2006.
72. S. R. Little, D. M. Lynn, Q. Ge et al., "Poly-β amino estercontaining microparticles enhance the activity of nonviral genetic vaccines," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9534-9539, 2004.
73. K. K. L. Phua, K. W. Leong, and S. K. Nair, "Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format," Journal of Controlled Release, vol. 166, no. 3, pp. 227-233, 2013.
74. X. Su, J. Fricke, D. G. Kavanagh, and D. J. Irvine, "In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles," Molecular Pharmaceutics, vol. 8, no. 3, pp. 774-787, 2011.
75. K. K. L. Phua, S. K. Nair, and K. W. Leong, "Messenger RNA (mRNA) nanoparticle tumour vaccination," Nanoscale, vol. 6, no. 14, pp. 7715-7729, 2014.
76. K. K. L. Phua, H. F. Staats, K. W. Leong, and S. K. Nair, "Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity," Scientific Reports, vol. 4, article 5128, 2014.
77. D. Boczkowski, S. K. Nair, D. Snyder, and E. Gilboa, "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo," Journal of Experimental Medicine, vol. 184, no. 2, pp. 465-472, 1996.
78. S. K. Nair, S. Hull, D. Coleman, E. Gilboa, H. K. Lyerly, and M. A. Morse, "Induction of carcinoembryonic antigen (CEA)- specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA," International Journal of Cancer, vol. 82, no. 1, pp. 121-124, 1999.
79. P. Ponsaerts, V. F. I. Van Tendeloo, and Z.N. Berneman, "Cancer immunotherapy usingRNA-loaded dendritic cells," Clinical and Experimental Immunology, vol. 134, no. 3, pp. 378-384, 2003.
80. D. Dörfel, S. Appel, F. Grünebach et al., "Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA," Blood, vol. 105, no. 8, pp. 3199-3205, 2005.
81. F. Grünebach, K. Kayser, M. M. Weck, M. R. Müller, S. Appel, and P. Brossart, "Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes," Cancer Gene Therapy, vol. 12, no. 9, pp. 749-756, 2005.
82. S. Nair, D. Boczkowski, M. Fassnacht, D. Pisetsky, and E. Gilboa, "Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity," Cancer Research, vol. 67, no. 1, pp. 371-380, 2007.
83. N. Schaft, J. Dörrie, P. Thumann et al., "Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than beforematuration," Journal of Immunology, vol. 174, no. 5, pp. 3087-3097, 2005.
84. G. Schuler, B. Schuler-Thurner, and R. M. Steinman, "The use of dendritic cells in cancer immunotherapy," Current Opinion in Immunology, vol. 15, no. 2, pp. 138-147, 2003.
85. A. Heiser, D. Coleman, J. Dannull et al., "Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors," The Journal of Clinical Investigation, vol. 109, no. 3, pp. 409-417, 2002.
86. M. A. Morse, S. K. Nair, D. Boczkowski et al., "The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer," International Journal of Gastrointestinal Cancer, vol. 32, no. 1, pp. 1-6, 2002.
87. M. A. Morse, S. K. Nair, P. J. Mosca et al., "Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA," Cancer Investigation, vol. 21, no. 3, pp. 341-349, 2003.
88. D. Boczkowski, S. K. Nair, J.-H. Nam, H. K. Lyerly, and E. Gilboa, "Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells," Cancer Research, vol. 60, no. 4, pp. 1028-1034, 2000.
89. E. Gilboa and J. Vieweg, "Cancer immunotherapy with mRNAtransfected dendritic cells," Immunological Reviews, vol. 199, pp. 251-263, 2004.
90. F. Grünebach, M. R. Müller, A. Nencioni, and P. Brossart, "Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes," Gene Therapy, vol. 10, no. 5, pp. 367-374, 2003.
91. C. Milazzo, V. L. Reichardt, M. R. Müller, F. Grünebach, and P. Brossart, "Induction ofmyeloma-specific cytotoxic T cells using dendritic cells transfectedwith tumor-derivedRNA," Blood, vol. 101, no. 3, pp. 977-982, 2003.
92. A. Nencioni, M. R. Müller, F. Grünebach et al., "Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer," Cancer Gene Therapy, vol. 10, no. 3, pp. 209-214, 2003.
93. P. Thumann, I. Moc, J. Humrich et al., "Antigen loading of dendritic cells with whole tumor cell preparations," Journal of Immunological Methods, vol. 277, no. 1-2, pp. 1-16, 2003.
94. A. Bonehill, A. M. T. Van Nuffel, J. Corthals et al., "Singlestep antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients," Clinical Cancer Research, vol. 15, no. 10, pp. 3366-3375, 2009.
95. D. A. Caruso, L.M. Orme, A. M. Neale et al., "Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer," Neuro-Oncology, vol. 6, no. 3, pp. 236-246, 2004.
96. J. Dannull, Z. Su, D. Rizzieri et al., "Enhancement of vaccinemediated antitumorimmunity in cancer patients after depletion of regulatory T cells," Journal of Clinical Investigation, vol. 115, no. 12, pp. 3623-3633, 2005.
97. J. A. Kyte, G. Kvalheim, S. Aamdal, S. Sæbøe-Larssen, and G. Gaudernack, "Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination," Cancer Gene Therapy, vol. 12, no. 6, pp. 579-591, 2005.
98. S. K. Nair, M. Morse, D. Boczkowski et al., "Induction of tumorspecific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells," Annals of Surgery, vol. 235, no. 4, pp. 540-549, 2002.
99. D.H. Schuurhuis, P. Verdijk, G. Schreibelt et al., "In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients," Cancer Research, vol. 69, no. 7, pp. 2927-2934, 2009.
100. Z. Su, J. Dannull, A. Heiser et al., "Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells," Cancer Research, vol. 63, no. 9, pp. 2127-2133, 2003.
101. J. Dannull, S. Nair, Z. Su et al., "Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand," Blood, vol. 105, no. 8, pp. 3206-3213, 2005.
102. D. Benteyn, A. M. T. Van Nuffel, S. Wilgenhof, and A. Bonehill, "Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a trimix of costimulatory molecules," Methods in Molecular Biology, vol. 1139, pp. 3-15, 2014.
103. J. J. Pen, B. DeKeersmaecker, S.K. Maenhout et al., "Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70," The Journal of Immunology, vol. 191, no. 4, pp. 1976-1983, 2013.
104. + T cells," Blood, vol. 116, no. 22, pp. 4501-4511, 2010.
105. W. Hobo, T. I. Novobrantseva, H. Fredrix et al., "Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigenmRNA electroporation," Cancer Immunology, Immunotherapy, vol. 62, no. 2, pp. 285-297, 2013.
106. S. K. Pruitt, D. Boczkowski, N. de Rosa et al., "Enhancement of anti-tumor immunity through localmodulation of CTLA-4 and GITR by dendritic cells," European Journal of Immunology, vol. 41, no. 12, pp. 3553-3563, 2011.
107. R. D. Granstein, W. Ding, and H. Ozawa, "Induction of antitumor immunity with epidermal cells pulsed with tumorderived RNA or intradermal administration of RNA," Journal of Investigative Dermatology, vol. 114, no. 4, pp. 632-636, 2000.
108. F. Martinon, S. Krishnan, G. Lenzen et al., "Induction of virusspecific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA," European Journal of Immunology, vol. 23, no. 7, pp. 1719-1722, 1993.
109. W.-Z. Zhou, D. S. B. Hoon, S. K. S. Huang et al., "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization," Human Gene Therapy, vol. 10, no. 16, pp. 2719-2724, 1999.
110. J.D. Wolchok, H. Kluger, M. K. Callahan et al., "Nivolumab plus Ipilimumab in advanced melanoma," The New England Journal of Medicine, vol. 369, no. 2, pp. 122-133, 2013.